AstraZeneca

AstraZeneca's Tagrisso recommended for EU approval by CHMP for unresectable EGFR-mutated lung cancer, based on LAURA Phase III trial showing extended median progression-free survival to over three years.

The atopic dermatitis market is projected to grow from $7.51 billion in 2023 to $15.27 billion by 2028, driven by advancements in biologic therapies, personalized medicine, and product innovations. Key players include Sanofi SA, Regeneron Pharmaceuticals Inc., and Novartis International AG.

AstraZeneca announced CHMP's positive opinion to extend Tagrisso's indication for treating inoperable non-small-cell lung cancer with EGFR mutations in exon 19 deletions or L858R mutation in exon 21, for patients not progressing after chemotherapy. This is based on a phase III study with 216 participants. Tagrisso is currently approved in around 100 markets.

Lung cancer is a leading cause of cancer death globally, with NSCLC being the most common type. LAURA is a Phase III trial testing Tagrisso, a third-generation EGFR-TKI, in Stage III EGFRm NSCLC patients. Tagrisso has shown efficacy in various stages of NSCLC and is part of AstraZeneca's comprehensive lung cancer portfolio. The company aims to redefine cancer care and eliminate it as a cause of death.

EMA does not recommend AstraZeneca for those with capillary bleeding syndrome, citing it as a side effect. EMA also investigates heart muscle inflammation cases post-vaccination with all COVID-19 vaccines.

Lunit's shares surged after announcing a partnership with AstraZeneca to develop AI-based digital pathology solutions for non-small cell lung cancer (NSCLC). The collaboration will use Lunit’s Genotype Predictor to predict EGFR mutations in NSCLC using H&E-stained slide images, offering a quicker and more accurate diagnostic process. The partnership aims to enhance AI technology in clinical applications and expand patient eligibility for EGFR-targeted therapies.

Lunit and AstraZeneca collaborate to develop AI-powered digital pathology solutions, focusing on Lunit SCOPE Genotype Predictor, which predicts NSCLC driver mutations from H&E slide images, aiming to improve diagnostic workflows and patient outcomes.

Lunit signs strategic collaboration with AstraZeneca to develop AI-based digital pathology solutions for non-small cell lung cancer, marking its first direct contract with a global Big Pharma headquarters. The partnership aims to enhance precision medicine and improve treatment outcomes for lung cancer patients, with plans to expand collaboration to other cancer mutations.

Sarilumab more effective than methotrexate in enabling steroid taper in polymyalgia rheumatica patients, according to ACR Convergence 2024 data.